|Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy|
JH Elliott, F Wightman, A Solomon, K Ghneim, J Ahlers, MJ Cameron, ...
PLoS pathogens 10 (11), 2014
|Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring|
JH McMahon, MR Jordan, K Kelley, S Bertagnolio, SY Hong, CA Wanke, ...
Clinical Infectious Diseases, ciq167, 2011
|Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study|
JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, ...
The lancet HIV 2 (12), e520-e529, 2015
|Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low-and middle-income countries: a systematic review and meta-analysis|
TS Boender, KCE Sigaloff, JH McMahon, S Kiertiburanakul, MR Jordan, ...
Clinical Infectious Diseases 61 (9), 1453-1461, 2015
|Viral suppression after 12 months of antiretroviral therapy in low-and middle-income countries: a systematic review|
JH McMahon, JH Elliott, S Bertagnolio, R Kubiak, MR Jordan
Bulletin of the World Health Organization 91, 377-385, 2013
|Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …|
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
|The HIV care cascade: a systematic review of data sources, methodology and comparability|
NA Medland, JH McMahon, EPF Chow, JH Elliott, JF Hoy, CK Fairley
Journal of the International AIDS Society 18 (1), 20634, 2015
|Poverty, hunger, education, and residential status impact survival in HIV|
J McMahon, C Wanke, N Terrin, S Skinner, T Knox
AIDS and Behavior 15 (7), 1503-1511, 2011
|Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority …|
JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ...
The lancet HIV 5 (5), e211-e220, 2018
|HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 …|
DE Bennett, MR Jordan, S Bertagnolio, SY Hong, G Ravasi, JH McMahon, ...
Clinical infectious diseases 54 (suppl_4), S280-S289, 2012
|Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004–2011|
MR Jordan, DE Bennett, MA Wainberg, D Havlir, S Hammer, C Yang, ...
Clinical infectious diseases 54 (suppl_4), S245-S249, 2012
|Broad activation of latent HIV-1 in vivo|
K Barton, B Hiener, A Winckelmann, TA Rasmussen, W Shao, K Byth, ...
Nature communications 7 (1), 1-8, 2016
|Repeated assessments of food security predict CD4 change in the setting of antiretroviral therapy|
JH McMahon, CA Wanke, JH Elliott, S Skinner, AM Tang
Journal of acquired immune deficiency syndromes (1999) 58 (1), 60, 2011
|Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review|
JH McMahon, JH Elliott, SY Hong, S Bertagnolio, MR Jordan
PLoS One 8 (2), 2013
|Barriers and strategies to achieve a cure for HIV|
MC Pitman, JSY Lau, JH McMahon, SR Lewin
The Lancet HIV 5 (6), e317-e328, 2018
|The safety and effect of multiple doses of vorinostat on HIV transcription in HIV-infected patients receiving combination antiretroviral therapy|
J Elliott, A Solomon, F Wightman, M Smith, S Palmer, M Prince, J Watson, ...
Conference on Retroviruses and Opportunistic Infections, 3-6, 2013
|Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India|
JH McMahon, A Manoharan, CA Wanke, S Mammen, H Jose, T Malini, ...
AIDS and Behavior 17 (6), 2253-2259, 2013
|Is hospital-in-the-home (HITH) treatment of bacterial endocarditis safe and effective?|
JH McMahon, JM O'keeffe, Victorian HITH Outcomes Study Group, ...
Scandinavian journal of infectious diseases 40 (1), 40-43, 2008
|Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy|
KJ Siefried, L Mao, LA Cysique, J Rule, ML Giles, DE Smith, J McMahon, ...
AIDS (London, England) 32 (1), 35, 2018
|Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a …|
P Cahn, R Kaplan, PE Sax, K Squires, JM Molina, A Avihingsanon, ...
The Lancet HIV 4 (11), e486-e494, 2017